Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Additional hetero ring which is unsaturated

Subclass of:

544 - Organic compounds -- part of the class 532-570 series

544000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

544000000 - HETEROCYCLIC CARBON COMPOUNDS CONTAINING A HETERO RING HAVING CHALCOGEN (I.E., OXYGEN, SULFUR, SELENIUM, OR TELLURIUM) OR NITROGEN AS THE ONLY RING HETERO ATOMS (Class 540, subclass 1)

544001000 - Hetero ring is six-membered having two or more ring hetero atoms of which at least one is nitrogen (e.g., selenazines, etc.)

544224000 - The six-membered hetero ring consists of two nitrogens and four carbons (e.g., 1,2-diazines, etc.)

544242000 - 1,3-diazines

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
544333000 Additional hetero ring which is unsaturated 38
20080255358Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases - Disclosed are imidazopyridine compounds having the formula:10-16-2008
20090023922PROCESS FOR PREPARING VORICONAZOLE, NEW POLYMORPHIC FORM OF INTERMEDIATE THEREOF, AND USES THEREOF - The present invention relates to an improved process for preparation of Voriconazole and Voriconazole (1R)-(−)-10-camphorsulfonate.01-22-2009
20090062541Process for catalytically preparing aromatic or heteroaromatic nitriles - The present invention relates to a process for preparing optionally substituted aromatic or heteroaromatic nitriles starting from haloaromatics. These are reacted in a copper-catalysed reaction with potassium hexacyanoferrate(II) or potassium hexacyanoferrate(III) in the presence of heteroaromatic amines.03-05-2009
20090088571Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides - Disclosed is a multi-step process for preparing a compound of Formula I:04-02-2009
200901185066,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or, or pharmaceutically acceptable salts, esters, or prodrugs thereof:05-07-2009
20090124804Enantioselective process for preparing a substituted alkanoic acid - The present invention is directed to a process for enantioselectively preparing substituted piperidine alkanoic acid integrin antagonist compounds.05-14-2009
20090137805N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES - The present invention relates to novel amides and a process for preparing these amides.05-28-2009
20090149651PROCESSES AND INTERMEDIATES FOR PRODUCING AMINOBENZIMIDAZOLE UREAS - The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of bacterial gyrase and Topoisomerase IV (Topo IV).06-11-2009
20090264655PROCESS FOR PREPARING 2,3-DISUBSTITUTED INDOLES - Disclosed are processes for making 2, 3 disubstituted indole compounds such as compounds of general formula I comprised of the steps of 10-22-2009
20090299066TRIAZOLONE DERIVATIVES AS MMP INHIBITORS FOR THE TREATMENT OF ASTHMA AND COPD - The invention provides compounds of formula (I): wherein R12-03-2009
20100056784PROCESS FOR THE PREPARATION OF VORICONAZOLE - The present invention relates to an improved process for the preparation of Voriconazole.03-04-2010
20100063284SOLID FORMS OF 1-ethyl-3-(5-(5-FLUOROPYRIDIN-3-YL)-7-(PYRIMIDIN-2-YL)-1H-BENZO[D]IMIDAZO- L-2-YL)UREA - Solid forms of crystalline1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea, compositions containing solid forms of crystalline1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea and methods of using the same are described.03-11-2010
20100105905EP2 Agonists - The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma.04-29-2010
20100137594TETRAZOYLOXIME DERIVATIVE AND PLANT DISEASE CONTROL AGENT - According to the present invention, a tetrazoyloxime derivative and a salt thereof, which are excellent in a control effect against plant disease injury, and a plant disease controlling agent containing the same as an active ingredient are provided. The tetrazoyloxime derivative has a structure represented by formula (1) shown below:06-03-2010
20100292473PROCESS FOR PREPARING (2R,3S/2S,3R)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2- ,4-TRIAZOL-1-YL)BUTAN-2-OL - Voriconazole is prepared by a process comprising condensing 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazole-1-yl)ethanone with 4-chloro-6-ethyl-5-fluoropyrimidine, in a ketone, ether, aliphatic hydrocarbon, or aromatic hydrocarbon solvent, to give (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-diflurophenyl)-1-(1H-1,2,4-triazole-1-yl)butan-2-ol.11-18-2010
20110144334ISOXAZOLINE-SUBSTITUTED BENZAMIDE COMPOUND AND PESTICIDE - An isoxazoline-substituted benzamide compound of formula (1) or a salt thereof:06-16-2011
20120065396ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME - The present invention relates to an amide compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition comprising the same. The inventive amide compound facilitates bone formation and inhibits bone loss, and is therefore useful for preventing and treating bone disorders such as osteoporosis, osteodystrophy, bone fracture, periodontal disease, Paget's disease, bone metastasis, and rheumatoid arthritis.03-15-2012
20120142922BENZAMIDE DERIVATIVES - Disclosed are benzamide derivatives useful in slowing the expansion of cancer cells.06-07-2012
20120178933Organic Compound, Benzoxazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using Benzoxazole Derivative - Novel benzoxazole derivatives are provided to reduce driving voltage of light-emitting elements, and to reduce power consumption of light-emitting elements, light-emitting devices, and electronic devices. A benzoxazole derivative represented by the general formula (G1) is provided. Since the benzoxazole derivative represented by the general formula (G1) has an electron-injecting property, the benzoxazole derivative can be suitably used for light-emitting elements, light-emitting devices, and electronic devices.07-12-2012
20120184741SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDRO- FURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA - The present application is directed to solid forms of compounds of formula (I):07-19-2012
20120184742PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS - The present application is directed to compounds, intermediates and methods for preparing compounds of formula (I)07-19-2012
20120190852MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA - The present invention is to provide a medical composition for the treatment or prophylaxis of glaucoma which comprises a pyridylaminoacetic acid compound represented by the formula (1):07-26-2012
20120220772NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE08-30-2012
20130046095N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof - The invention concerns compounds of general formula (I), wherein n, X02-21-2013
20130184460GLYCINE TRANSPORTER INHIBITING SUBSTANCES - The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, pain, and sleep disorder:07-18-2013
20130261304Organic Compound, Benzoxazole Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Device Using the Benzoxazole Derivative - Novel benzoxazole derivatives are provided to reduce driving voltage of light-emitting elements, and to reduce power consumption of light-emitting elements, light-emitting devices, and electronic devices. A benzoxazole derivative represented by the general formula (G1) is provided. Since the benzoxazole derivative represented by the general formula (G1) has an electron-injecting property, the benzoxazole derivative can be suitably used for light-emitting elements, light-emitting devices, and electronic devices.10-03-2013
20130261305PROCESS OF MAKING GYRASE AND TOPOISOMERASE INHIBITORS - The present application is directed to compounds, intermediates and methods for preparing compounds of formula (I)10-03-2013
20130317222SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYD- ROFURAN-2-YL]-1H-BENZIMIDAZOL-2-YL]UREA - The present application is directed to solid forms of compounds of formula (I):11-28-2013
20130324728PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST - The present invention is directed to processes for preparing a pyridyl piperidine compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.12-05-2013
20140005393SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY01-02-2014
20140051855PENTA-SUBSTITUTED TETRAHYDROPYRIMIDINES WITH AGGREGATION-INDUCED EMISSION CHARACTERISTICS AND PREPARATION METHOD AND USE THEREOF - The present invention provides a series of penta-substituted tetrahydropyrimidines with aggregation-induced emission (AIE) characteristics and preparation method and use thereof. The AIE penta-substituted tetrahydropyrimidines have structures shown as formula (I). R02-20-2014
20140066625Fused Imidazole Derivatives Useful as IDO Inhibitors - Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleanine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.03-06-2014
20140081025HETEROAROMATIC RING DERIVATIVE - The compound represented by formula (IA)03-20-2014
20140107340Benzamides - The present invention is directed to benzamide containing compounds which inhibit the P2X7 receptor04-17-2014
20140316136NOVEL ORGANIC ELECTROLUMINESCENCE COMPOUNDS AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING SAME - The present invention relates to novel organic electroluminescence compounds and an organic electroluminescence device comprising the same. The organic electroluminescence compound according to the present invention has an advantage of manufacturing an OLED device having long operating lifespan due to its high luminous efficiency compared with conventional materials, and having reduced power consumption induced by improved power efficiency.10-23-2014
20140350252PROCESS FOR THE PREPARATION OF VORICONAZOLE AND INTERMEDIATES THEREOF - The present invention relates to an improved stereoselective process for the preparation of (2R,3S/2S,3R)-3-(4-chloro-5-fluoropyrimidin-6-yl)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol intermediate compound. This intermediate compound is further used to prepare voriconazole—a triazole antifungal agent.11-27-2014
20140357866NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME - The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device containing the same. Using the organic electroluminescent compounds of the present invention, it is possible to manufacture an OLED device with a long operating lifespan and high luminous efficiency. In addition, the compounds can improve the power efficiency of the device to reduce overall power consumption.12-04-2014
20160130278GLYCINE TRANSPORTER INHIBITOR - The present invention provides novel compounds of formula [IA] or pharmaceutically acceptable salts thereof:05-12-2016

Patent applications in class Additional hetero ring which is unsaturated

Website © 2023 Advameg, Inc.